The Role of the Kidney and Sodium-Glucose Cotransporter-2 Inhibition in Diabetes Management
Author:
- Virginia ValentineVVVirginia Valentine
Open Access
- 1 October 2012
- journal article
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 30 (4) , 151-155
Abstract
IN BRIEF: The kidney plays an important role in glucose homeostasis and has become a target for the treatment of hyperglycemia in type 2 diabetes. This review discusses the role of the kidney in glucose homeostasis and how inhibition of renal glucose reabsorption may become a novel treatment option for type 2 diabetes.Keywords
This publication has 25 references indexed in Scilit:
- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of InsulinAnnals of Internal Medicine, 2012
- Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humansKidney International, 2011
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal TubuleJournal of the American Society of Nephrology, 2011
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and ExerciseDiabetes Care, 2010
- SGLT2 inhibition — a novel strategy for diabetes treatmentNature Reviews Drug Discovery, 2010
- Prevalence and Trends in Obesity Among US Adults, 1999-2008JAMA, 2010
- Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic RatsDiabetes, 2008
- AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB ratAmerican Journal of Physiology-Endocrinology and Metabolism, 2002
- Contributions of theAmerican Journal of Physiologyto the discovery of insulinAmerican Journal of Physiology-Endocrinology and Metabolism, 1998
- Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.Journal of Clinical Investigation, 1987